Valneva: article on Lyme vaccine in The Lancet
These trials, together with a third Phase II trial in pediatric participants, supported the design of the ongoing pivotal Phase III trial VALOR (Vaccine Against Lyme for Outdoor Recreationists)", the vaccine company points out.
Pfizer plans to submit a marketing authorization application to the US FDA, and another marketing authorization application to the European Medicines Agency in 2026, subject to positive data.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction